Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate
Sponsored by Calliditas Therapeutics AB (Sweden)
Active
$641.6K Funding
5 People
External
Related Topics
clinical trial,
drug therapy,
liver disease,
biomarker,
immunology
People
Geoffrey Block
Principal Investigator (PI)
Medicine
﹒Clinical Professor, Medicine
Ryan Akhbari
(CD)
Liver Research Institute
﹒Clinical Research Coordinator II
Tausif Chowdhury
(CD)
College of Nursing
﹒Clinical Research Coordinator II
Kirsten Anderson
(CD)
Senior VP Health Sciences
﹒Research Compliance Administrator IV
Jason Gass
(CD)
Liver Research Institute
﹒Research Data Support Specialist II